Summary (3)

• Genotype non-1

  • SVR 78% 24 weeks with 800 mg RBV
  • Increasing duration and/or dose of RBV gave no increase in efficacy

• Shorter treatment associated with fewer SAEs and withdrawals for safety

• Lower dose RBV associated with fewer

  • SAEs (24 weeks)
  • RBV dose modifications
  • Large decreases in haemoglobin

Previous slide

Next slide

Back to first slide

View graphic version